Related Experiment Video
Updated: Apr 21, 2026
04:33
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.8K
[Relapse and insomnia in unipolar major depression]
Linda Falussy1, Petra Balla, Ede Frecska
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Pszichiátriai Tanszék, Debrecen, Hungary. efrecska@hotmail.com.
Summary
Treating sleep disorders is crucial for preventing depression relapses and chronicity. Early insomnia treatment may prevent mood disorder development, highlighting the link between sleep and mental health.
Area of Science:
- Psychiatry and Neuroscience
- Sleep Medicine
Context:
- Mood and sleep disorders frequently co-occur, impacting biological psychiatric research.
- Epidemiological data confirm a high prevalence of comorbid mood and sleep disturbances.
Purpose:
- To evaluate the necessity of treating sleep disorders in the context of mood disorder relapse, remission, and recurrence.
- To explore the neurobiological links and therapeutic implications of treating sleep disorders for mood disorders.
Summary:
- Insomnia significantly increases depression risk (10-fold) and is linked to relapses, recurrence, and chronicity.
- Shared neurobiological features include altered melatonin levels, advanced sleep phases, imbalanced monoaminergic pathways, and REM sleep abnormalities.
- Persistent sleep abnormalities post-remission may increase relapse risk, while early insomnia treatment may prevent mood disorder onset.
Impact:
- Highlights the importance of addressing sleep disorders as a preventative and therapeutic strategy for mood disorders.
- Suggests that targeting sleep abnormalities could offer novel pathophysiological and therapeutic insights in psychiatry.
- Underscores the role of neural plasticity in the comorbidity of sleep, mood, anxiety, and dementia disorders.
Related Concept Videos
01:27Insomnia
614
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
614
01:19Management of Insomnia
761
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
761
01:23Antidepressant Drugs: MAOIs and Other Agents
1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
01:27Depressive Disorders: MDD and Dysthymia
1.2K
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
1.2K
01:14CNS Depressants: Barbiturates and Benzodiazepines
1.8K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.8K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.2K